Inhibiting receptor tyrosine kinases (e.g., EGFR)—STAT3 is downstream of receptor tyrosine kinases such as EGFR, and persistent STAT3 activation due to aberrant EGFR signaling is well established in NSCLC [31,59]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.